Electrophysiological and biochemical effect of zinc oxide nanoparticles on heart functions of male Wistar rats.

Zinc oxide nanoparticles (ZnO NPs) are one of the most abundantly used nanomaterials in cosmetics and topical products, and nowadays, they are explored in drug delivery and tissue engineering. Some recent data evidenced that they are responsible for cardiotoxic effects and systemic toxicity. The present study aimed to investigate the toxic effect of ZnO NPs (39 nm) on the heart of Wistar rats and to perform a dose-response relationship using three different dose levels (25, 50, 100 mg/kg bw) of ZnO NPs on the electrocardiogram (ECG) readings, the levels of biochemical function parameters of heart, and the oxidative stress and antioxidant biomarkers. Furthermore, zinc concentration level and histopathological examination of heart tissues were determined. ZnO NPs showed a dose-dependent effect, as the 100 mg/kg bw ZnO NPs treated group showed the most significant changes in ECGs parameters: R-R distance, P-R interval, R and T amplitudes, and increased levels of heart enzymes Creatine Kinase- MB (CK-MB) and Lactate dehydrogenase (LDH). On the other hand, elevated zinc concentration levels, oxidative stress biomarkers MDA and NO, and decreased GSH levels were found also in a dose-dependent manner, the results were supported by impairment in the histopathological structure of heart tissues. While the dose of 100 mg/kg bw of ZnO bulk group showed no significant effects on heart function. The present study concluded that ZnO NPs could induce cardiac dysfunctions and pathological lesions mainly in the high dose.

Comparative study of zinc oxide nanoparticles and its bulk form on liver function of Wistar rat.

Zinc oxide nanoparticles (ZnO NPs) are produced in high tonnage each year; they are widely used in consumer and industrial products, also now finding applications in bioimaging and drug delivery. In the present study, comparison between ZnO NPs (39 nm) and its bulk/micron form (particle size = 5 µm) on liver function of rats was determined. In our study, liver enzymes biomarkers, serum lipid profile, zinc concentration, and histopathological examination in liver tissues were used to evaluate liver injury. Moreover, lipid peroxidation (malondialdehyde), nitric oxide, and reduced glutathione levels were determined to detect the oxidation-reduction process in liver tissue. The results showed dose-dependent toxicity of ZnO NPs. Three different dose levels (25, 50, and 100 mg/kg bw) were used, and the 100-mg/kg bw ZnO NPs group showed the most significant changes in liver enzymes and histopathological structure, as well as redox state. The dose of 100 mg/kg bw of ZnO bulk group showed no significant effects on liver function. The study concluded that ZnO NPs caused hepatic impairments.